Group 1 - Gilead Sciences (GILD.US) experienced a decline of 1.8% in after-hours trading, closing at $144.55 [1]

Core Viewpoint - The company, Sihuan Pharmaceutical (00460), has announced a positive earnings forecast, expecting revenue of at least 2.5 billion RMB for the year ending December 31, 2025, representing a growth rate of over 30% compared to the previous year [1][5]. Group 1: Financial Performance - The company anticipates a net profit of no less than 150 million RMB for the same period [1][5]. - The growth in performance is primarily driven by the rapid expansion of the medical aesthetics business, which is expected to generate over 1.4 billion RMB in revenue and over 700 million RMB in segment profit, with both metrics showing an annual growth rate exceeding 90% [1][5]. Group 2: Business Segments - The medical aesthetics segment has become the largest contributor to both revenue and profit for the company, significantly boosting overall performance [1][5]. - The innovative drug business is entering a harvest phase, which is expected to improve the company's profit structure [1][5]. Group 3: Financial Health - The company maintains a robust financial position with ample cash reserves, having conducted multiple rounds of share buybacks and completed the spin-off of Xuan Bamboo Biotechnology, which has optimized the financial structure and driven profit breakthroughs [1][5].

Core Viewpoint - Gilead Sciences reported a 5% year-over-year revenue growth in Q4, reaching $7.9 billion, surpassing analyst expectations of $7.7 billion [1] - The adjusted earnings per share (EPS) were $1.86, exceeding the forecast of $1.81 [1] Financial Performance - Q4 revenue increased to $7.9 billion, up from the previous year [1] - Sales of HIV-related products rose by 6% to $5.8 billion, driven by increased demand for prevention and treatment [1] - Sales of Remdesivir declined by 37% to $212 million, primarily due to a decrease in COVID-19 related hospitalizations [1] Future Outlook - Gilead expects product sales to range between $29.6 billion and $30 billion for the year [1] - The adjusted EPS guidance is projected to be between $8.45 and $8.85, while analysts expect $30.2 billion and $8.75 respectively [1] - The guidance is influenced by a pricing agreement with the Trump administration and uncertainties following the expiration of certain government subsidies [1]

2月10日，三大指数涨跌不一，创新药板块表现强势。截至当日收盘，恒生沪深港创新药精选50指数 (HSSSHID.HK)上涨2.26%收获六连阳，该指数成分股中，信立泰上涨近7%，石药集团与荣昌生物 （A）上涨超5%，信达生物上涨近5%。 海通国际证券指出，港股医药板块经历前期连续调整后，市场情绪有所回暖。随着港股业绩期临近，我 们看好业绩确定性强的互联网医疗、CXO/科研服务龙头。此外，我们建议持续关注本轮调整中回调幅 度较大的优质创新药龙头企业。 相关ETF方面，wind金融终端显示，截至当日收盘，创新药ETF天弘（517380）成交额超3700万元。资 金流向方面，截至2月9日，该ETF已连续3个交易日获资金净流入，累计净流入额为4166.12万元。该 ETF最新流通份额为25.04亿份，最新流通规模为19.63亿元。此外，生物医药ETF（159859）当日成交 额超1亿元，居同标的产品第一。该ETF最新流通份额为95.96亿份，最新流通规模为37.96亿元。 （文章来源：21世纪经济报道） 创新药ETF天弘（517380）为全市场唯一一只跟踪恒生沪港深创新药精选50指数的ETF，汇聚中国硬核 创新药力量 ...

Summary of BMS Q4 2025 and Full Year Performance Company Overview - The document discusses Bristol-Myers Squibb (BMS), a major player in the pharmaceutical industry, focusing on its Q4 2025 and full-year performance metrics. Key Financial Metrics - **Q4 2025 Revenue**: BMS achieved revenue of $12.5 billion, with growth portfolio sales at $7.4 billion (+15%) and legacy portfolio sales at $5.1 billion (-16%) [1] - **Full Year 2025 Revenue**: Total revenue for 2025 was $48.2 billion (-1%), with growth portfolio sales at $26.4 billion (+17%) and legacy portfolio sales at $21.8 billion (-16%) [1] 2026 Revenue Guidance - BMS updated its 2026 revenue guidance to a range of $46 billion to $47.5 billion (-5% to -1%) [2] - Non-GAAP EPS guidance was set between $6.05 and $6.35 per share [2] Product Performance Highlights Oncology - **Opdivo (Nivolumab)**: Sales reached $2.69 billion (+7%), driven by volume growth and new approvals [2] - **Yervoy (Ipilimumab)**: Sales were $810 million (+18%) [2] - **Opdualag**: Sales of $350 million (+37%), with a 30%+ market share in 1L melanoma in the US [2] Hematology - **Revlimid (Lenalidomide)**: Sales dropped to $600 million (-55%) due to generic competition [2] - **Pomalyst**: Sales were $690 million (-16%) [2] - **Reblozyl**: Sales increased to $670 million (+21%), driven by demand for 1L treatment of MDS-related anemia [2] - **Breyanzi**: Sales reached $390 million (+47%), primarily driven by demand in LBCL [2] Cardiovascular - **Eliquis (Apixaban)**: Sales were $3.45 billion (+6%), with US and ex-US sales growing by 4% and 9% respectively; 2026 global revenue growth is expected at 10% to 15% [3] - **Camzyos**: Sales of $350 million (+57%) [3] - **Milvexian**: Phase 3 clinical study terminated due to interim analysis not meeting efficacy [3] Immunology - **Orencia (Abatacept)**: Sales remained stable at $1.01 billion [3] - **Sotyktu**: Sales of $86 million (+3%), with a PDUFA date for PsA indication set for March 6, 2026 [3] Neurology - **Cobenfy**: Sales of $51 million [3] - **Zeposia**: Sales of $160 million (-1%), primarily contributed by MS indication [3] Additional Insights - The document highlights the impact of generic competition on legacy products and the growth potential in the growth portfolio, particularly in oncology and cardiovascular segments [2][3] - The anticipated decline in revenue for Eliquis in 2027 is noted, with a projected drop of $1.5 billion to $2 billion [3]

Summary of Key Points from Conference Call Industry Overview - The Chinese stock market showed mixed performance with the Shanghai Composite Index down by 0.02% and the ChiNext Index down by 0.14% while the STAR 50 Index increased by 0.80% [1] - The total trading volume in the A-share market was 1.41 trillion RMB, indicating a relatively quiet trading day [1] Core Insights - AI applications and media stocks led the market gains, driven by investor anticipation for updates from domestic AI model developers [1] - The healthcare sector also saw gains, with a shift in the CDMO (Contract Development and Manufacturing Organization) field from beta-driven to visibility-driven growth, suggesting a focus on high-certainty compound growth targets for 2026 [1] - The Chinese healthcare sector is expected to perform strongly in 2025, primarily due to the global expansion of emerging assets [1] - Biotechnology, pharmaceuticals, and CRO/CDMO sectors are leading the market, contrasting with negative returns in other sectors [1] Additional Important Information - The white liquor sector experienced a decline, leading the market downwards, along with corrections in the real estate and agriculture sectors [2] - Cash transaction volumes are continuously shrinking, indicating a cautious market sentiment [3] - Current fund flow preferences lean towards selling, with a configuration ratio of 1.06 times, while buying is focused on gold, lithium, and GPU sectors, and selling is occurring in memory and defense sectors [3]

Core Viewpoint - The stock of Gilead Sciences-B (01672) has increased over 30% in the month, with a current price of HKD 18.24 and a trading volume of HKD 17.99 million, following the announcement of its first oral glucagon-like peptide-1 receptor agonist, ASC36, entering clinical development [1] Group 1 - The company announced on February 11 that it has selected ASC36 oral tablets for clinical development, with plans to submit an Investigational New Drug (IND) application to the FDA in the second quarter of 2026 for obesity treatment [1] - ASC36 is expected to have superior oral bioavailability and efficacy compared to a recently FDA-approved GLP-1R agonist, potentially allowing for lower dosing [1] - The weight loss effect per milligram of ASC36 peptide is anticipated to be more effective, which may lead to lower manufacturing costs due to scalability advantages [1] Group 2 - ASC36 is developed using the company's proprietary Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) technology [1] - The oral tablet formulation of ASC36 has been optimized using the company's proprietary POTENT technology for effective oral peptide delivery [1]

Core Viewpoint - The stock of Gilead Sciences-B (01672) has increased by over 30% in the month, with a current rise of 6.42% to HKD 18.24, driven by the announcement of its first oral glucagon-like peptide-1 receptor agonist, ASC36, entering clinical development [1] Company Developments - On February 11, Gilead Sciences-B announced that its board has selected ASC36 oral tablets for clinical development [1] - The company plans to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for ASC36 in the second quarter of 2026 for the treatment of obesity [1] Product Advantages - ASC36 is expected to have superior oral bioavailability and efficacy compared to a recently FDA-approved GLP-1R agonist, potentially allowing for lower dosing [1] - Each milligram of ASC36 peptide is anticipated to provide better weight loss effects, which may lead to lower manufacturing costs due to scalability advantages [1] Technology and Innovation - ASC36 is developed using Gilead's proprietary Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) technology [1] - The oral tablet formulation of ASC36 has been optimized using Gilead's proprietary POTENT technology for effective oral peptide delivery [1]

Core Viewpoint - Four Seasons Pharmaceutical (00460) anticipates significant revenue growth, projecting at least 2.5 billion RMB in revenue and a net profit of at least 150 million RMB for the fiscal year ending December 31, 2025, driven primarily by its aesthetic medicine business and innovative drug segment [1] Group 1: Financial Performance - The company expects revenue growth exceeding 30% compared to the same period last year, with a projected revenue of no less than 2.5 billion RMB [1] - The net profit is anticipated to be at least 150 million RMB, indicating a strong financial outlook [1] Group 2: Business Segments - The aesthetic medicine segment is expected to generate over 1.4 billion RMB in revenue and over 700 million RMB in segment profit, with both metrics showing annual growth rates exceeding 90% [1] - The innovative drug business is entering a harvest phase, significantly improving the company's profit structure [1] Group 3: Financial Health - The company maintains a robust financial position with ample cash reserves, having executed multiple rounds of share buybacks [1] - The successful spin-off of Xuan Zhu Bio has optimized the company's financial structure, contributing to profit breakthroughs [1]

Core Viewpoint - Four Seasons Pharmaceutical (00460) anticipates significant revenue growth, projecting at least 2.5 billion RMB in revenue and 150 million RMB in net profit for the fiscal year ending December 31, 2025, driven primarily by its aesthetic medicine business and innovative drug segment [1] Group 1: Financial Performance - The company expects revenue growth of over 30% compared to the same period last year, with a minimum revenue target of 2.5 billion RMB [1] - Net profit is projected to be no less than 150 million RMB for the same period [1] Group 2: Business Segments - The aesthetic medicine segment is expected to generate over 1.4 billion RMB in revenue and over 700 million RMB in segment profit, with both metrics showing an annual growth rate exceeding 90% [1] - The innovative drug business is entering a harvest phase, significantly improving the company's profit structure [1] Group 3: Financial Health - The company maintains a robust financial position with ample cash reserves [1] - Multiple rounds of share buybacks have been implemented, and the successful spin-off of Xuan Bamboo Biotechnology has optimized the company's financial structure, contributing to profit breakthroughs [1]